Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m(2) per day for 5 days) of fludarabine and 8 infus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Treon, Steven P., Branagan, Andrew R., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Turnbull, Barry, Wasi, Parveen, Emmanouilides, Christos, Frankel, Stanley R., Lister, Andrew, Morel, Pierre, Matous, Jeffrey, Gregory, Stephanie A., Kimby, Eva
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2009
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2670786/
https://ncbi.nlm.nih.gov/pubmed/19015393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-09-177329
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados